Quotient Sciences wins in all 2022 CRO Leadership Award categories
Quotient has been recognized with multiple 2022 CRO Leadership Awards in Quality, Expertise, Capabilities, Compatibility and Reliability, including two Champion Awards. The CRO Leadership Awards recognizes top performing outsourcing organizations in the drug development arena. Quotient received leadership awards in all five categories.
Mark Egerton featured in Pharma's Almanac roundtable article: What important company milestone do you anticipate reaching in 2022?
In this roundtable with Pharma's Almanac, Mark Egerton, CEO of Quotient Sciences, answers the Question 'What important company milestone do you anticipate reaching in 2022?'
Mark Egerton, CEO of Quotient Sciences has been featured in an article in Global Business Reports: A Shifting Landscape; The outsourcing model is here to stay
Mark Egerton, CEO of Quotient Sciences has been featured in and article in Global Business Reports
Mark Egerton, CEO, Quotient Sciences: Interview with Global Business Reports
Mark Egerton, CEO, Quotient Sciences: Interview with Global Business Report
Quotient Sciences' CEO, Mark Egerton, featured in 2022 edition of U.S. Pharma and Biopharma Report
In this interview, Mark Egerton, CEO of Quotient Sciences, states that "Quotient Sciences wants to support our customers with their molecules earlier in the development process, from the point at which the drug candidate molecule is selected from the discovery program."
Quotient Sciences SME comments on solubility & bioavailability challenges in Drug Development & Delivery feature article
John McDermott, Quotient Sciences' Executive Drug Development Consultant, discusses Integrated Development Strategies Overcome Solubility Challenges, in Drug Development & Delivery's Special Feature.